Friday, January 30, 2026

NVIDIA Surges Again! Stock Hits $123.51 as AI Hype Grows!

NVIDIA surged over 2% following a positive report from Bain & Company, reclaiming a market capitalization of $3 trillion.

Design Finalized, Construction of North Korean Human Rights Center Set for 2026 Completion

The National Center for North Korean Human Rights is set to break ground in October, aiming to raise awareness about human rights issues.

Kim Unveils “Hwasong-20” ICBM as China and Russia’s Top Officials Attend North Korea’s Anniversary Parade

Kim Jong Un showcased the new Hwasong-20 ICBM at the Workers' Party anniversary, emphasizing North Korea's nuclear status and alliances.

Jin Joong Hwang

Author's Latest

Unlocking Convenience: Rolvedon’s Same-Day Chemotherapy Solution for Neutropenia Revealed

Hanmi Pharmaceutical's Rolvedon shows potential for same-day chemotherapy administration, improving patient convenience and market competitiveness.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

HK inno.N’s New Drug K-CAB Applies for U.S. FDA Approval: How Innovative Is the P-CAB Therapy?

HK inno.N's K-Cap for GERD has entered the U.S. approval process, showing superior results in clinical trials over existing treatments.

How Neurophet AQUA is Transforming Dementia Diagnosis in South Korea: Key MOU Insights

Neurophet partners with Eisai Korea to enhance dementia screening and diagnostics using AI-based software, Neurophet AQUA.

Revolutionizing Kidney Stone Surgery: Roen Surgical’s AI Robot Zamenix Launches in Indonesia

Roen Surgical exports AI-powered kidney stone surgery robot Zamenix to Indonesia, enhancing surgical precision and safety in healthcare.

SK Biofarm, FDA Approved Radioactive Method: Will it be a Revolutionary Cancer Cure with SLK 33501?

SK Biopharmaceuticals gains FDA approval for Phase 1 trials of radiopharmaceuticals SKL35501 and SKL35502, advancing cancer treatment.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Samsung Biologics Targets Japan’s $12.3 Billion CDMO Market: What You Need to Know

Samsung Biologics expands in Japan, targeting top pharma firms with new CMO brand 'ExellenS' and enhancing production capabilities.

Lotte Biologics Unveils Dual-Site Strategy: A Game Changer for Global CDMO in 2027

Lotte Biologics aims to lead in the evolving biotech landscape with dual sites in the U.S. and South Korea, enhancing global supply chains.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

The Next Trillion-Dollar Bet: Korean Pharma Invests in Immuno-Oncology, Targeting a $1 Trillion Global Market

Cho Yong-joon outlines Dongkoo Bio's transformation into a global healthcare leader, emphasizing convergence and innovative growth strategies.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.